地塞米松泪管插入剂治疗临床显著水液缺乏型干眼:一项随机对照试验
这项单中心双盲随机对照试验纳入75例临床显著水液缺乏型干眼患者,采用双眼自身对照设计,一眼接受地塞米松0.4毫克泪管插入剂(30天缓释),对侧眼接受假处理(胶原栓)。结果显示地塞米松插入眼在第4周角膜染色和第4周、第6周结膜染色显著减少,Schirmer湿长两组相当,患者报告症状无统计学显著差异;第4周地塞米松治疗眼眼压升高5-10毫米汞柱的可能性更高(9眼 vs 1眼;相对危险度9.00;95%CI 1.14-71.0)。作者认为,在认为局部糖皮质激素治疗合适时,地塞米松泪管插入剂或可考虑作为临床显著水液缺乏型干眼的一种无滴眼液双重治疗。
要点
- 地塞米松插入眼第4周角膜染色平均差-0.55(95%CI -0.91至-0.19),结膜染色第4周平均差-0.68(95%CI -1.05至-0.30)、第6周平均差-0.34(95%CI -0.65至-0.02)。
- Schirmer湿长两组相当,患者报告症状无统计学显著差异。
- 第4周地塞米松治疗眼眼压升高5-10毫米汞柱者9眼 vs 1眼,相对危险度9.00(95%CI 1.14-71.0),均经短期局部β受体阻滞剂处理后消退。
核心结论
- 作者认为,在认为局部糖皮质激素治疗合适时,地塞米松泪管插入剂或可考虑作为临床显著水液缺乏型干眼的一种无滴眼液双重治疗。
研究设计与样本
- 单中心、双盲随机对照试验,纳入75例成人临床显著水液缺乏型干眼患者。
- 采用1:1随机序列决定每例患者哪只眼接受地塞米松0.4毫克泪管插入剂(30天缓释时间)或假处理(胶原栓),对侧眼接受相反处理。
- 患者对治疗分配设盲,随访在第2、4、6周由设盲研究者进行。
主要发现
- 基线时两治疗臂(对侧眼)干眼严重程度相当。
- 地塞米松插入眼第4周角膜染色显著更少(平均差-0.55;95%CI -0.91至-0.19),结膜染色第4周(平均差-0.68;95%CI -1.05至-0.30)和第6周(平均差-0.34;95%CI -0.65至-0.02)显著更少。
- Schirmer湿长两治疗臂相当。
- 患者报告第4周地塞米松插入眼干涩更少(平均差-5.5;95%CI -11.4至0.4),但任何患者报告症状均无统计学显著差异。
- 第4周地塞米松治疗眼更可能出现眼压升高5-10毫米汞柱(9眼 vs 1眼;相对危险度9.00;95%CI 1.14-71.0),所有眼压升高病例经短期局部β受体阻滞剂处理均消退。
关键数值与推荐
- 入组标准:综合眼表染色评分≥3(0-12)、角膜荧光素染色评分≥2(0-6)、双眼5分钟Schirmer湿长<10毫米,且有症状(干涩、眼部不适或视疲劳,≥30[0-100]),尽管已使用至少1种处方滴眼液治疗,并被认定适合局部糖皮质激素治疗。
临床怎么用
- 作者认为,在认为局部糖皮质激素治疗合适时,地塞米松泪管插入剂或可考虑作为临床显著水液缺乏型干眼的一种无滴眼液双重治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate a commercially available dexamethasone intracanalicular insert to treat dry eye. DESIGN: Single-center, double-masked randomized controlled trial. PARTICIPANTS: Patients with clinically significant aqueous-deficient dry eye (combined ocular surface staining score, ≥ 3 [0-12]; corneal fluorescein staining score, ≥ 2 [0-6]; and Schirmer's wetting, < 10 mm at 5 minutes in both eyes) with symptoms (dryness, eye discomfort, or visual fatigue, ≥ 30 [0-100]) despite treatment with at least 1 prescription drop and deemed candidates for topical steroid therapy. METHODS: Seventy-five adult patients were enrolled. A 1:1 randomization sequence was used to determine which eye of each patient would receive the treatment (dexamethasone 0.4-mg intracanalicular insert with 30-day elution time) or sham (collagen plug). The fellow eye received the opposite treatment. Patients were masked to treatment assignment. Follow-up visits (at weeks 2, 4, and 6) were performed by a masked investigator. MAIN OUTCOME MEASURES: Dry eye parameters and patient symptoms were used for efficacy, and intraocular pressure (IOP) was used for safety assessment. RESULTS: The severity of dry eye was comparable between the treatment arms (fellow eyes) at baseline. Eyes that received the dexamethasone insert showed significantly less corneal staining at week 4 (mean difference [MD], -0.55; 95% confidence interval [CI], -0.91 to -0.19) and conjunctival staining at week 4 (MD, -0.68; 95% CI, -1.05 to -0.30) and week 6 (MD, -0.34; 95% CI, -0.65 to -0.02). Schirmer's wetting was comparable between the two treatment arms. Although the patients reported less dryness in eyes that received the insert at week 4 (MD, -5.5; 95% CI, -11.4 to 0.4), no statistically significant differences were found in any patient-reported symptoms. At week 4, dexamethasone-treated eyes were more likely to show an IOP increase (by 5-10 mmHg; 9 eyes vs. 1 eye; relative risk, 9.00; 95% CI, 1.14-71.0). All cases of increased IOP were managed with short-term topical β-blockers and subsided. CONCLUSIONS: The dexamethasone intracanalicular insert may be considered a dropless dual treatment for clinically significant aqueous-deficient dry eye when topical steroid treatment is deemed appropriate. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Lin MX, Guo L, Saldanha IJ, et al. Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye: A Randomized Controlled Trial. Ophthalmology. 2024. PMID: 38492864. doi:10.1016/j.ophtha.2024.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。